Lars D. Engstrom
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)Mirati Therapeutics (United States)(US)
Publications by Year
Research Areas
Cancer-related gene regulation, Lung Cancer Treatments and Mutations, Biochemical and Molecular Research, Lung Cancer Research Studies, Protein Kinase Regulation and GTPase Signaling
Most-Cited Works
- → The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients(2019)1,249 cited
- → Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations(2014)574 cited
- → Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor(2022)475 cited
- → PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models(2015)458 cited
- → PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations(2015)268 cited